Drug Price Trends for BUPRENORPHINE-NALOXONE

Average Pharmacy Cost for BUPRENORPHINE-NALOXONE

These are average pharmacy acquisition costs (net of discounts) from a US national survey

Drug Name	NDC	Price/Unit ($)	Unit	Date
BUPRENORPHINE-NALOXONE 8-2 MG SL TABLET	65162-0415-03	0.75109	EACH	2025-03-19
BUPRENORPHINE-NALOXONE 12-3 MG SL FILM	00378-8768-16	4.66170	EACH	2025-03-19
BUPRENORPHINE-NALOXONE 12-3 MG SL FILM	00378-8768-93	4.66170	EACH	2025-03-19
BUPRENORPHINE-NALOXONE 12-3 MG SL FILM	43598-0581-30	4.66170	EACH	2025-03-19

Market Analysis and Price Projections for Buprenorphine-Naloxone

Market Size and Growth Projections

The buprenorphine and naloxone market is experiencing significant growth driven by several key factors. As of 2024, the market size is estimated to be around USD 4.73 billion and is projected to reach USD 5.82 billion by 2029, growing at a Compound Annual Growth Rate (CAGR) of 4.23% during the forecast period[1].

Driving Factors

Increasing Substance Use Disorders

The global increase in opioid addiction and dependence is a major driver of the market. According to the StatPearls Journal, opioid use disorders affect over 16 million people worldwide and more than 2.1 million people in the United States each year[1].

Advantages of Buprenorphine and Naloxone

Buprenorphine and naloxone offer effective treatment for opioid use disorder (OUD) and are preferred due to their efficacy in managing withdrawal symptoms and reducing the risk of relapse. A cost-effectiveness analysis published in the Annals of Internal Medicine showed that buprenorphine-naloxone is preferable to extended-release naltrexone in most scenarios, especially when considering quality-adjusted life-years (QALYs) and time abstinent from opioids[2].

Rising Prevalence of Pain Disorders

The growing prevalence of acute and chronic pain disorders, including postoperative pain, also contributes to the market growth. In the United States, more than 80% of patients suffer from postoperative pain, which increases the demand for buprenorphine and naloxone for effective pain management[1].

Regional Market Analysis

North America

North America holds a significant share in the global buprenorphine and naloxone market. This is attributed to the high prevalence of substance use disorders, acute and chronic pain disorders, and supportive government initiatives. For instance, the Substance Abuse and Mental Health Services Administration (SAMHSA) has proposed rule changes to expand access to treatment for OUD, including the use of telehealth for initiating buprenorphine treatment[1].

Asia Pacific

The Asia Pacific region is expected to be the fastest-growing market during the forecast period. This growth is driven by increasing awareness of opioid use disorder treatment, expanding government initiatives, and the rising prevalence of substance use disorders in the region[1].

Market Segments

Generics Segment

The generics segment is projected to show significant growth due to factors such as cost-effectiveness, patent expirations, and the increasing need for affordable treatment options. Generic buprenorphine and naloxone products offer similar efficacy at lower prices, making them more accessible to patients and healthcare systems[1].

Key Players

Major players in the buprenorphine and naloxone market include Indivior PLC, Viatris Inc. (Mylan Inc.), Sandoz AG, Dr. Reddy's Laboratories Ltd., and Hikma Pharmaceuticals PLC. These companies play a crucial role in driving innovation and accessibility in addiction care solutions[1].

Price Trends and Projections

Current Pricing

The cost of buprenorphine-naloxone varies depending on the dosage and form. For example, a supply of 30 sublingual tablets of 2 mg-0.5 mg buprenorphine-naloxone can cost around $65, while a supply of 30 sublingual films of the same dosage can cost from $57.21 to $65.43[5].

Long-Term Projections

The global buprenorphine market, which includes buprenorphine-naloxone combinations, is projected to grow significantly. By 2037, the global buprenorphine market is expected to reach USD 35.75 billion, growing at a CAGR of 14.4% from 2024 to 2037[3].

Cost-Effectiveness

A study published in the Annals of Internal Medicine highlighted the cost-effectiveness of buprenorphine-naloxone compared to extended-release naltrexone. The analysis showed that buprenorphine-naloxone is preferable in most scenarios, considering both healthcare sector and societal perspectives, due to its higher efficacy and lower costs in terms of quality-adjusted life-years (QALYs) and time abstinent from opioids[2].

Government Initiatives and Reimbursement Policies

Government initiatives and favorable reimbursement policies are crucial in driving the market growth. For instance, the proposed rule change by SAMHSA to expand access to treatment for OUD, including the use of telehealth, is expected to increase the usage of buprenorphine and naloxone. Additionally, favorable reimbursement policies in regions like North America further propel market growth by improving patient affordability and access to treatment[1][4].

Key Takeaways

• The buprenorphine and naloxone market is expected to grow from USD 4.73 billion in 2024 to USD 5.82 billion by 2029.
• The market is driven by increasing substance use disorders, the advantages of buprenorphine and naloxone, and the rising prevalence of pain disorders.
• North America holds a significant market share, while the Asia Pacific region is expected to be the fastest-growing market.
• The generics segment is projected to show significant growth due to cost-effectiveness and patent expirations.
• Government initiatives and favorable reimbursement policies are key drivers of market growth.

FAQs

1. What is the current market size of the buprenorphine and naloxone market?

The buprenorphine and naloxone market size is expected to reach USD 4.73 billion in 2024[1].

2. What is the projected growth rate of the buprenorphine and naloxone market?

The market is expected to grow at a CAGR of 4.23% from 2024 to 2029[1].

3. Which region is expected to be the fastest-growing market for buprenorphine and naloxone?

The Asia Pacific region is estimated to grow at the highest CAGR over the forecast period[1].

4. What are the key factors driving the growth of the buprenorphine and naloxone market?

The growth is driven by increasing substance use disorders, the advantages of buprenorphine and naloxone, and the rising prevalence of pain disorders[1].

5. How does the cost-effectiveness of buprenorphine-naloxone compare to extended-release naltrexone?

Buprenorphine-naloxone is generally more cost-effective than extended-release naltrexone, especially when considering QALYs and time abstinent from opioids[2].

Sources

1. Mordor Intelligence: Buprenorphine And Naloxone Market Size & Share Analysis.
2. Annals of Internal Medicine: Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
3. DrugPatentWatch: Drug prices and trends for buprenorphine.
4. Grand View Research: Naltrexone And Buprenorphine Market Size Report, 2030.
5. Drugs.com: Buprenorphine/naloxone Prices, Coupons, Copay Cards & Patient Assistance.